超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

細胞X
CytomX是一家開發抗體治療藥物的公司

CytomX是一家開發下一代高靶向抗體治療技術的生物技術公司。我們的愿景是用更安全、更有效的療法改變生活。

CytomX's Probody? Platform represents a disruptive approach to discovering and developing empowered antibodies to treat areas of major unmet medical need. This novel platform is enabling the development of a diversified pipeline of empowered antibodies, including Probodies, Probody-Drug Conjugates (PDCs), bispecifics, multispecifics and other formats, addressing previously undruggable targets in cancer, inflammation and other areas of significant unmet medical need.

Through precise targeting of the disease microenvironment, Probodies have the potential to address diseases in ways that have not been possible to-date, enabling a new level of tissue targeting, selectivity and activation. CytomX has optimized its Probody Platform and established preclinical proof of concept for Probodies.

To accomplish its mission, the CytomX team embraces its corporate values of integrity, commitment, creativity, teamwork, accountability and fun.

CytomX Therapeutics Inc. was formed in 2010 from a precursor company, CytomX LLC, originally spun out of University of California, Santa Barbara in 2006. CytomX is led by a seasoned and proven management team and is well-financed by leading life science investors, including Third Rock Ventures, Canaan Partners and the Roche Venture Fund.